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tober 22, 2013.his study sought to examine the possible drug–drug interactions between clopidogrel and morphine.Background Because morphinedthe recommended treatment for pain of myocardial infarctiondis associated with poor clinical
outcome, we hypothesized that morphine lowers the plasma levels of clopidogrel active metabolite as well as its
effects on platelets.Methods Twenty-four healthy subjects received a loading dose of 600 mg clopidogrel together with placebo or 5 mg morphine
intravenously in a randomized, double-blind, placebo-controlled, cross-over trial. Pharmacokinetics was determined by
liquid chromatography tandemmass spectrometry, and clopidogrel effects were measured by platelet function tests.Results Morphine injection delayed clopidogrel absorption (p ¼ 0.025) and reduced the area under the curve levels of its
active metabolite by 34% (p ¼ 0.001). Morphine delayed the maximal inhibition of platelet aggregation on average
by 2 h (n ¼ 24; p < 0.001). Residual platelet aggregation was higher 1 to 4 h after morphine injection (n ¼ 24;
p < 0.005). Furthermore, morphine delayed the inhibition of platelet plug formation under high shear rates
(P2Y-Innovance; n ¼ 21; p < 0.004) and abolished the 3-fold prolongation in collagen adenosine diphosphate-
induced closure times seen in extensive and rapid metabolizers (n ¼ 16; p ¼ 0.001).Conclusions Morphine delays clopidogrel absorption, decreases plasma levels of clopidogrel active metabolite, and retards and
diminishes its effects, which can lead to treatment failure in susceptible individuals. (Drug Drug Interactions of
Aspirin and P2Y12-inhibitors; NCT01369186) (J Am Coll Cardiol 2014;63:630–5) ª 2014 by the American
College of Cardiology FoundationThe P2Y12-receptor inhibitor clopidogrel blocks adenosine-
diphosphate (ADP)-induced platelet function in vivo, and
combination of P2Y12-inhibitors with aspirin has become a
mainstay for the treatment of patients with acute coronary
syndromes (1,2).
Clopidogrel is a pro-drug that requires metabolic activa-
tion by cytochrome P450 enzymes in 2 steps (3), explaining
its relatively slow onset of action.
Although morphine is recommended for pain relief in
myocardial infarction (MI) (1), data for its net beneﬁt fromPharmacology, Medical University of Vienna,
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revised manuscript received October 22, 2013,randomized controlled trials are lacking. Interestingly, the
use of morphine is associated with higher mortality in
patients with non–ST-segment elevation acute coronary
syndromes (4) and with delayed activity of prasugrel or
ticagrelor in ST-segment elevation MI patients (5).
Although this is not a causal proof, there might be a bio-
logically plausible cause–effect relationship: opiates inhibit
gastric emptying, which delays absorption and might
decrease peak plasma levels of oral drugs (6).
Hence, we hypothesized that morphine lowers the plasma
levels of clopidogrel active metabolite as well as its anti-
platelet effects and examined drug–drug interactions bet-
ween morphine and clopidogrel.
Methods
Experimental design and blood collection. A double-
blind, block-randomized, placebo-controlled, cross-over
trial was conducted in accordance with good clinical prac-
tice guidelines and the Declaration of Helsinki to evaluate
the effect of morphine on the intestinal absorption,
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and Acronyms
ADP = adenosine-
diphosphate
AUC = area under the curve
CADP-CT = collagen/ADP
induced closure times
MI = myocardial infarction
VASP = vasodilator-
stimulated-phosphoprotein
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631pharmacokinetics, and pharmacodynamics of clopidogrel.
The study was approved by the Ethics Committee of the
Medical University of Vienna and the Austrian National
Competent Authority; written informed consent was ob-
tained from all healthy subjects (n ¼ 24).
Key inclusion criteria were:18 years of age; non-pregnant;
and ability to comprehend the full nature and purpose of the
study. Key exclusion criteria were: intake of non-steroidal anti-
inﬂammatory drugs or platelet inhibitors; known coagulation
disorders; relevant impairment of renal or hepatic function;
chronic infectious diseases (human immunodeﬁciency virus,
hepatitis B and C); clinically relevant abnormal laboratory
values; and contraindications for clopidogrel or morphine.
Secretaries conducted randomization by using www.
randomization.com, and prepared individually sealed opa-
que envelopes. Morphine (5 mg intravenous bolus; Vendal,
G.L. Pharma, Lannach, Austria) or placebo (0.9% sodium
chloride) was prepared by unblinded pharmacists and
injected by blinded physicians. A minimum wash-out period
of 14 days was chosen, because it exceeds platelet survival
in vivo and because the effect of P2Y12-inhibition dimi-
nishes within 5 days (7) (Fig. 1).
After an overnight fast, a loading dose of 600 mg clopi-
dogrel (Plavix, Sanoﬁ-Aventis, Vienna, Austria) was admin-
istered with 250 ml tap water immediately after the injection
of placebo or morphine. No food, drink, or tobacco was
permitted for 4 h.
Blood sampling times for pharmacodynamic and phar-
macokinetic evaluations after study drug administration
are depicted in Figures 2 to 4. Blood was collected with an
intravenous catheter after drawing a waste sample. TheFigure 1 Schematic of Trial Design
HCl ¼ hydrogen chloride.analysts were also blinded with
regard to the sequence of periods.
Assessment of pharmaco-
kinetics and pharmacodynamics.
Clopidogrel effects were measured
with the following assays: the
vasodilator-stimulated-phospho-
protein (VASP) phosphorylation
assay (8); multiple electrode
aggregometry (9); where the in-
tercept of the individual down-
slope and the plateau phase was plotted graphically for the
area under the curve (AUC) to estimate the onset of the
maximum effect; and the platelet function analyzer under
high shear rates (10), where the onset of the maximum
effect was deﬁned as the ﬁrst of 3 consecutive measurements
of >300 s. Pharmacokinetics were assessed by liquid
chromatography tandem mass spectrometry (11), and
subjects were genotyped as described previously (12) for
CYP2C9 and CYP2C19 polymorphisms for exploratory
reasons only, to allow comparisons of the effect size of
morphine with genetic determinants of clopidogrel
pharmacokinetics.
Statistical analysis. Pharmacokinetic calculations were
made with Kinetica 2000 (version 3.0, InnaPhase Corpo-
ration, Philadelphia, Pennsylvania). The primary pharma-
cokinetic outcome variable was the AUC of clopidogrel
active metabolite, as usual for drug interaction studies; all
other comparisons were considered secondary.
Data are presented as means for demographic data and
medians for outcome variables in the text. Changes in
Figure 2
Morphine Lowers Plasma Concentrations of
Clopidogrel Active Metabolite
Healthy volunteers (n ¼ 24) received a 600-mg loading dose concomitantly with a
placebo or 5 mg morphine. p < 0.001 repeated measures analysis of variance;
*p < 0.05; **p  0.01 designate differences between treatments (Wilcoxon test).
Data present medians without error bars for reasons of clarity.
0
Figure 3 Morphine Retards and Decreases Clopidogrel Effects
Adenosine-diphosphate (ADP)-induced aggregation was measured by whole-blood
aggregometry (n ¼ 24) and with the P2Y- cartridge of the platelet function analyzer
(n ¼ 21). p < 0.001 repeated measures analysis of variance; *p < 0.05;
**p  0.01 designate differences between treatments (Wilcoxon test). Data
present mean  95% conﬁdence interval.
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Wilcoxon signed rank tests, accounting for the skewed
distributions of the measurements. To assess the robustness
of results, for the outcome variables showing a signiﬁcant
effect in these analyses, a mixed-model was additionally
ﬁtted to test for period and carry-over effects.
The Mann-Whitney U test was used for an exploratory
comparison between individuals with different metabolizer
status. Statistical calculations were performed with commer-
cially available software (IBM SPSS Statistics, Version 20,
IBM, Chicago, Illinois) and SAS (version 9.3, SAS, Cary,
North Carolina). In all cases, 2-sided p values 0.05 were
considered signiﬁcant.Results
Demographic characteristics of subjects and adverse
events. Healthy volunteers (17 men, 7 women) were 32 9
years of age, had 75  11 kg, and a body mass index of 24 
3 kg/m2.Morphine injection caused mild to moderate adverse
events in 50% of subjects, including ﬂush (42%), pressure
on the chest (25%), nausea (25%), fatigue (17%), headache
(8%), and xerostomia (8%).
Pharmacokinetics. Morphine injection delayed maximal
plasma concentrations of clopidogrel (Tmax: 105 vs. 83 min,
p ¼ 0.025) (Table 1) and reduced both the Cmax of clopi-
dogrel active metabolite (from 171 to 113 ng/ml, p ¼ 0.025)
(Fig. 2) and the total exposure as measured by the AUC0-n
by 34% (16,840 vs. 11,103 ng  h/ml, p ¼ 0.001).
Pharmacodynamics. Co-administration of morphine de-
layed the time required to maximally inhibit platelet aggre-
gation 2-fold (3 vs. 1.25 h, p < 0.001) and, in some
cases, even up to 5 h. Residual platelet aggregation was higher
1 to 4 h after morphine injection (p < 0.005) (n ¼ 24).
Morphine also delayed the inhibition of platelet plug
formation under high shear rates (the median IC100 was
observed 75 vs. 45 min with the P2Y-Innovance cartridge:
p < 0.004) (Fig. 3) (n ¼ 21). Clopidogrel intake prolonged
the conventional collagen/ADP induced closure times
Figure 4 Morphine Blunts Clopidogrel Effects
Vasodilator-stimulated-phosphoprotein (VASP)-phosphorylation was measured by ﬂow-cytometry (n ¼ 10), and the collagen adenosine diphosphate closure time was measured
with the platelet function analyzer (n ¼ 23). *p < 0.05; **p < 0.01 vs. baseline; #p < 0.05 for absolute change between treatments (Wilcoxon test). Data present mean  95%
conﬁdence interval. CADP-CT ¼ collagen/ADP induced closure times.
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633(CADP-CT) 6 h after intake from a median of 110 to 162 s
(p < 0.01) under placebo but not when morphine was co-
administered (105 to 106 s, p ¼ 0.97) (n ¼ 23; p ¼ 0.012
between treatments).
Clopidogrel reduced the median platelet reactivity index
in the VASP phosphorylation assay from a median of 81%
to 41% (p ¼ 0.008; n ¼ 10) and trend-wise less after
morphine (87% vs. 59%, p ¼ 0.004; p ¼ 0.30 between
treatments) (Fig. 4).
All signiﬁcant differences between treatments were
conﬁrmed in the mixed-model analysis accounting for carry-
over and period effects. No signiﬁcant carry-over and period
effects were observed for any of the outcome parameters
except for the 90-min time point in the P2Y-assay (p ¼
0.04) and the change in CADP-CT (p ¼ 0.024), which are
expected due to multiple comparisons.
Genetic polymorphisms. Subjects with normal and
impaired clopidogrel metabolism were compared in an
exploratory fashion (Table 2). Median values of Cmax andTable 1 Pharmacokinetic Parameters of Clopidogrel and its Active M
Parameter
Clopidogrel
Placebo Morphine p Value
Cmax (ng/ml) 5 (2–14) 5 (2–12) 0.753
Tmax (min) 83 (68–105) 105 (60–180) 0.025
AUC0–n (ng  h/ml) 662 (409–1,467) 704 (333–1,743) 1.000
Values are median (interquartile range); n ¼ 24.
AUC ¼ area under the curve.AUC of clopidogrel active metabolite decreased in the
following order: rapid>extensive>intermediate>poor
metabolizers. Morphine causes a “poor metabolizer pheno-
type” in individuals genetically prone to extensively metab-
olize clopidogrel (Fig. 2).
Clopidogrel increased the median CADP-CT from 108
to 241 s (p ¼ 0.001) in extensive or rapid metabolizers
(n ¼ 16) but failed to prolong CADP-CT in intermediate
or poor metabolizers (n ¼ 8; 118 to 109 s; p ¼ 0.812;
p ¼ 0.035 between groups). In contrast, almost all subjects
reached the maximum closure time with the P2Y-cartridge.
The only exception was a poor metabolizer in the morphine
period.Discussion
This trial identiﬁed a novel and potentially relevant drug–
drug interaction: morphine slows clopidogrel absorption,etabolite After a Loading Dose of 600 mg
Clopidogrel Active Metabolite
Placebo Morphine p Value
171 (116–215) 113 (83–142) 0.025
60 (45–75) 68 (60–90) 0.205
16,840 (11,719–21,543) 11,103 (9,779–17,948) 0.001
Table 2 Exploratory Analysis of Genetic Polymorphisms and Differences in Clopidogrel Active Metabolite
Impaired Metabolizers Normal Metabolizers
p Value
(Between Metabolic Groups)
n 4 3 1 10 6
Polymorphisms CYP2C19*2 CYP2C19*2 CYP2C9*2*3 CYP2C19*1 CYP2C9*17
Genotype Heterozygous Homozygous
Compound
Heterozygous Wild-type Heterozygous
Phenotype (metabolizer) Intermediate Poor Poor Extensive Rapid
Cmax (ng/ml) morphine 81 (71–121) 114 (92–232) 0.19
Placebo 101 (79–149) 199 (141–238) 0.009
p value 0.077 0.088
AUC (ng  h/ml) morphine 9,339 (7,687–10,572) 12,467 (11,036–18,973) <0.001
Placebo 10,465 (7,495–15,582) 19,129 (13,634–23,254) 0.004
p value 0.289 0.017
Values are median (interquartile range).
AUC ¼ area under the curve.
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and diminishes clopidogrel effects.
The pharmacokinetics in the placebo period was consis-
tent with a 600-mg loading dose, whereas morphine reduced
the gastrointestinal absorption of clopidogrel and caused a
pharmacokinetic proﬁle similar to a 300-mg loading dose
(11). This indicates the comparability of the enrolled pop-
ulation with previous trials and supports the external validity
of the trial.
Morphine retarded the absorption of clopidogrel
(increased Tmax), consequently led to low initial concentra-
tions of its active metabolite, and thereby delayed the
pharmacodynamic response on average by 2 h. The residual
platelet reactivity was signiﬁcantly higher after morphine
injection. The importance of rapid platelet inhibition in
the setting of MI is perhaps best demonstrated by the early
reduction of primary outcome events within the ﬁrst hours
by prasugrel versus clopidogrel (13).
Levels of the active metabolite were 2- to 4-fold higher
30 to 90 min after placebo compared with morphine in-
jection, which resulted in higher exposure; this is also re-
ﬂected by the different platelet function tests (Fig. 3). The
lower active metabolite concentrations after morphine
correspond to a reduction of the loading dose from 600 to
300 mg (14), which might lead to higher rates of major
adverse coronary events, including MI and death (15).
Morphine reduced the levels of the active metabolite to
concentrations usually observed in intermediate or poor
metabolizers (Fig. 2), who are prone to poor clinical
outcome (16). Hence, we consider the reduction of the
active metabolite to be clinically relevant.
What are possible consequences of our trial? Co-
administration of morphine and clopidogrel should likely
be avoided, if possible. More potent P2Y12-inhibitors might
provide greater efﬁcacy when morphine is injected, but
their interaction with morphine should be evaluated in
further trials.
Study limitations. Limitations of the trial include that the
VASP phosphorylation assay was only performed in asubset of subjects, because the method was added when the
trial was already ongoing and therefore does not allow
further subgroup analysis. Also, the trial was not powered
to measure differences in effects between different metab-
olizers. Additionally, the trial was not designed to char-
acterize the well-known half-life or pharmacodynamics for
24 h. However, aggregometry data indicate that differences
diminish after 4 h. We observed clopidogrel concentrations
and effects for 6 h only, because morphine is injected to
treat acute pain due to myocardial necrosis, and because the
full effects of a 600-mg loading dose are usually seen within
2 h (17). Finally, the cross-over design required investi-
gation of healthy volunteers rather than ST-segment
elevation MI patients, whose gastrointestinal absorption
might be further compromised (e.g., by reduced splanchnic
blood ﬂow) (18).
Conclusions
Concomitant injection of morphine slows clopidogrel
absorption, decreases plasma levels of its active metabolite,
and retards and diminishes its effects.Acknowledgments
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